YHD1119 + Lyrica

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Peripheral Nueropathy Pain

Conditions

Peripheral Nueropathy Pain

Trial Timeline

Jun 1, 2016 → Nov 1, 2016

NCT ID

NCT02783183

About YHD1119 + Lyrica

YHD1119 + Lyrica is a phase 1 stage product being developed by Yuhan for Peripheral Nueropathy Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02783183. Target conditions include Peripheral Nueropathy Pain.

What happened to similar drugs?

20 of 20 similar drugs in Peripheral Nueropathy Pain were approved

Approved (20) Terminated (4) Active (0)

✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved

✅Anplag Tab. 100mg bid + Anplag Tab. 100mg tidYuhanApproved

✅QUTENZA + Lidocaine + TramadolAstellas PharmaApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅Duloxetine + Pregabalin + PlaceboShionogiApproved

✅Mecobalamin IV Injection + Mecobalamin IM injection + Mecobalamin IV or IM injectionEisaiApproved

✅Ticagrelor + clopidogrelAstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02985216	Phase 3	Completed	Feb 7, 2017	May 2, 2018	Peripheral Neuropathic Pain
NCT02783183	Phase 1	Completed	Jun 1, 2016	Nov 1, 2016	Peripheral Nueropathy Pain
NCT02783638	Phase 1	Completed	Jan 1, 2016	Sep 1, 2016	Peripheral Neuropathy Pain

Competing Products

20 competing products in Peripheral Nueropathy Pain

See all competitors

Product	Company	Stage	Hype Score
SON-080	Sonnet BioTherapeutics	Phase 1/2	18
LY3857210 + Placebo	Eli Lilly	Phase 2	35
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mg	Yuhan	Approved	43
Anplag Tab. 100mg bid + Anplag Tab. 100mg tid	Yuhan	Approved	43
YHD1119 + Lyrica	Yuhan	Phase 1	29
YHD1119 + Lyrica	Yuhan	Phase 3	40
YHD1119 300mg + YHD1119 300mg	Yuhan	Phase 1	29
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsule	Daiichi Sankyo	Phase 2	35
edoxaban + Clopidogrel + Aspirin	Daiichi Sankyo	Phase 2	35
DS-5565 + placebo	Daiichi Sankyo	Phase 3	40
Mirogabalin + Placebo	Daiichi Sankyo	Phase 3	40
DS-5565	Daiichi Sankyo	Phase 3	40
Valemetostat Tosylate	Daiichi Sankyo	Phase 2	39
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo	Astellas Pharma	Phase 2	27
Qutenza	Astellas Pharma	Pre-clinical	26
QUTENZA + Lidocaine + Tramadol	Astellas Pharma	Approved	43
Qutenza exposure	Astellas Pharma	Pre-clinical	26
QUTENZA	Astellas Pharma	Phase 3	40
Qutenza + Pregabalin	Astellas Pharma	Approved	43
Capsaicin 8% + Placebo	Astellas Pharma	Phase 3	40